Because IRAK1/4 inhibitors attenuated PD-L1 on DP cells and the blockade of PD-L1 was also effective on elimination of DP cells, PD-L1 expression is partially regulated by innate immune stress signals in imatinib-insensitive CML LSCs. The gene discussed is IRAK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.